2006
DOI: 10.1016/j.clon.2006.03.017
|View full text |Cite
|
Sign up to set email alerts
|

Neurone-specific Enolase and Liver Metastasis in Small Cell Lung Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
9
0

Year Published

2008
2008
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 4 publications
0
9
0
Order By: Relevance
“…The overexpression and elevated serum levels of phosphoglycerate kinase 1 are shown in pancreatic ductal adenocarcinoma (35). Moreover, serum ENO2 is considered to be a prognostic factor in small cell lung, breast, and prostrate cancer (36)(37)(38)(39). Finally, PKM2 seems to be a more sensitive marker than conventional tumor markers such as CEA and CA72-4 for the post-operative surveillance of gastrointestinal cancer (40)(41)(42)(43)(44).…”
Section: Discussionmentioning
confidence: 99%
“…The overexpression and elevated serum levels of phosphoglycerate kinase 1 are shown in pancreatic ductal adenocarcinoma (35). Moreover, serum ENO2 is considered to be a prognostic factor in small cell lung, breast, and prostrate cancer (36)(37)(38)(39). Finally, PKM2 seems to be a more sensitive marker than conventional tumor markers such as CEA and CA72-4 for the post-operative surveillance of gastrointestinal cancer (40)(41)(42)(43)(44).…”
Section: Discussionmentioning
confidence: 99%
“…-Enolase (ENO1) is found in a variety of tissues, while -enolase (ENO3) is exclusively expressed in muscle tissues and -enolase (ENO2) is present in neurons and neuroendocrine tissues (Pancholi, 2001). ENO1 (EC 4.2.1.11) has been the focus of recent research owing to its multifunctional roles in diseases (Gerlt et al, 2005;Kim & Dang, 2005;Glasner et al, 2006;Liu & Shih, 2007) such as cancers (Katayama et al, 2006;Kanemoto et al, 2006;Gruber-Olipitz et al, 2004), autoimmune disorders (Mosca et al, 2006;Weleber et al, 2005;Kinloch et al, 2005;Gitlits et al, 2001), infections (Bergmann et al, 2005;Ehinger et al, 2004) and ischaemia (Anand & Stead, 2005). The disease-related roles of ENO1 mostly rely on its immunogenic properties (Fujii et al, 2005;Yoneda et al, 2007), DNA-binding ability (Al-Giery & Brewer, 1992;Subramanian & Miller, 2000;Wang et al, 2005) and plasmin(ogen) receptor function (Miles et al, 1991;Ehinger et al, 2004;Bergmann et al, 2005).…”
Section: Introductionmentioning
confidence: 99%
“…Compared with the patients with limited SCLC, patients suffering from extensive SCLC demonstrate significantly higher level of NSE. [13,14] At present, NSE serves as an important oncology indicator, particularly in the diagnosis and treatment of SCLC. [15] For suspected lung tumor patients, high NSE level (>100 ng/mL) suggests the high probability of SCLC, which should be discriminated from neuroendocrine tumor of other sites, liver tumor, lymphoma, and seminoma.…”
Section: Neuron-specific Enolasementioning
confidence: 99%